Strokes, Neurological, and Neuropsychiatric Disorders in COVID-19

Nooti, Sunil; Rai, Vikrant; Singh, Harbinder; Potluri, Veena; Agrawal, Devendra K.

doi:10.1007/978-981-16-5105-2_12

Cited by 3 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus is responsible for respiratory illnesses ranging from self-limited respiratory symptoms to severe pneumonia, including acute respiratory distress syndrome (ARDS), organ failure, and death [ 3 ]. Beyond the common symptoms of cough, fever, and loss of taste, COVID–19 is associated with a host of cardiovascular, neuropsychological, and hematological conditions, including thrombocytopenia, lymphopenia, leukocytosis, and disseminated intravascular coagulation (DIC) [ 2 , 4 , 5 ]. Patients suffering from hematological deficiencies are severely immunocompromised and are considered vulnerable subjects to severe disease progression.…”

Section: Introductionmentioning

confidence: 99%

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies

et al. 2023

View full text Add to dashboard Cite

The SARS-CoV-2 virus and the COVID-19 pandemic have spread across the world and severely impacted patients living with hematological conditions. Immunocompromised patients experience rapidly progressing symptoms following COVID-19 infection and are at high risk of death. In efforts to protect the vulnerable population, vaccination efforts have increased exponentially in the past 2 years. Although COVID-19 vaccination is safe and effective, mild to moderate side effects such as headache, fatigue, and soreness at the injection site have been reported. In addition, there are reports of rare side effects, including anaphylaxis, thrombosis with thrombocytopenia syndrome, Guillain-Barré Syndrome, myocarditis, and pericarditis after vaccination. Further, hematological abnormalities and a very low and transient response in patients with hematological conditions after vaccination raise concerns. The objective of this review is to first briefly discuss the hematological adverse effects associated with COVID-19 infection in general populations followed by critically analyzing the side effects and pathomechanisms of COVID-19 vaccination in immunocompromised patients with hematological and solid malignancies. We reviewed the published literature, with a focus on hematological abnormalities associated with COVID-19 infection followed by the hematological side effects of COVID-19 vaccination, and the mechanisms by which complications can occur. We extend this discussion to include the viability of vaccination efforts within immune-compromised patients. The primary aim is to provide clinicians with critical hematologic information on COVID-19 vaccination so that they can make informed decisions on how to protect their at-risk patients. The secondary goal is to clarify the adverse hematological effects associated with infection and vaccination within the general population to support continued vaccination within this group. There is a clear need to protect patients with hematological conditions from infection and modulate vaccine programs and procedures for these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…COVID-19 is characterized symptomatically by cough, fever, anosmia, ageusia, and cardiovascular, neurological, psychiatric, gastrointestinal, and hematological manifestations. Common hematological abnormalities include thrombocytopenia, lymphopenia, altered coagulation, and disseminated intravascular coagulation (DIC) [ 1 , 2 , 3 , 4 ]. Following hematological abnormalities during COVID-19 infectivity longitudinally during the disease course is critical because it not only allows access to the treatment response but also the disease severity.…”

Section: Introductionmentioning

confidence: 99%

A Review of Hematological Complications and Treatment in COVID-19

Yazdani,

Abdi,

Velpuri

et al. 2023

Hematology Reports

Self Cite

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, and its variants have spread rapidly across the globe in the past few years, resulting in millions of deaths worldwide. Hematological diseases and complications associated with COVID-19 severely impact the mortality and morbidity rates of patients; therefore, there is a need for oversight on what pharmaceutical therapies are prescribed to hematologically at-risk patients. Thrombocytopenia, hemoglobinemia, leukopenia, and leukocytosis are all seen at increased rates in patients infected with COVID-19 and become more prominent in patients with severe COVID-19. Further, COVID-19 therapeutics may be associated with hematological complications, and this became more important in immunocompromised patients with hematological conditions as they are at higher risk of hematological complications after treatment. Thus, it is important to understand and treat COVID-19 patients with underlying hematological conditions with caution. Hematological changes during COVID-19 infection and treatment are important because they may serve as biomarkers as well as to evaluate the treatment response, which will help in changing treatment strategies. In this literature review, we discuss the hematological complications associated with COVID-19, the mechanisms, treatment groups, and adverse effects of commonly used COVID-19 therapies, followed by the hematological adverse events that could arise due to therapeutic agents used in COVID-19.

show abstract